The company is effectively exiting its core immunotherapy program (Decoy20) and pivoting to an early-stage neurotechnology device, a completely new direction with no clinical data. Monitor for further details on the device's preclinical results and any strategic transactions or partnerships that could validate the new focus.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics reported Q3 2026 net loss of $1.0M ($0.01 per share), narrowed from $3.0M ($2.98) a year ago, driven by an 82% reduction in R&D spending to $0.3M as the company winds down its Decoy20 clinical program. The company raised $24M in a September private placement and is pivoting to early-stage research on a neurotechnology device for sleep conditions, a strategic shift away from its core immunotherapy pipeline.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $1.0M vs $3.0M in Q3 2025
- R&D expenses fell 82% to $0.3M from $1.5M
- G&A expenses fell 24% to $0.9M from $1.1M
- Cash and short-term investments of $30.6M at Sept 30, 2026
- Closed $24M private placement on Oct 16, 2026
- Company pivoting to neurotechnology device for sleep conditions, away from Decoy20 immunotherapy
- No revenue reported; pre-revenue clinical-stage biotech
Financial Impact
Net loss reduced by $2.0M YoY; cash position increased to $30.6M from $8.5M at Dec 31, 2025
Risk Factors
- No revenue and no active clinical development programs
- Strategic pivot to neurotechnology is unproven and early-stage
- Dilution from September 2026 private placement (20.3M shares issued)
- Activist stakeholders (Sino Lion, Yun Yao) hold ~53% combined, creating governance overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402956 |
Track record
20 reports on INDP
4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers